• About
  • EPISEEK
  • Solutions
    • Firefighters
  • Resources
    • News
  • Contact
  • Download Test Order Form
Order Tests Now
Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond

Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond

by Amy Cook | Oct 15, 2025 | Healthcare, News

Read Molika Ashford’s full article here. Or check out the summary below:  Tucson, AZ — Precision Epigenomics is taking a deliberate, tactical approach as it advances its EPISEEK test in the blood-based cancer screening field. While continuing to offer its Multi-Cancer...
Precision Epigenomics Joins the Conversation: Key Takeaways from Rosetta Fest

Precision Epigenomics Joins the Conversation: Key Takeaways from Rosetta Fest

by Amy Cook | Oct 14, 2025 | Healthcare, News

Tucson, AZ — The Precision Epigenomics team recently had an engaging and insightful experience at the Hint Summit at Rosetta Fest, a premier gathering for leaders in direct patient care. The conference served as a powerful platform for fostering collaboration and...
Precision Epigenomics Named “Startup of the Year” by University of Arizona, Honored for Pioneering Early Cancer Detection Technology

Precision Epigenomics Named “Startup of the Year” by University of Arizona, Honored for Pioneering Early Cancer Detection Technology

by Amy Cook | Oct 9, 2025 | Healthcare, News

Tucson, AZ — Precision Epigenomics, a molecular diagnostics innovator transforming cancer care, proudly announced today that it has been honored with the Startup of the Year award by the University of Arizona at the annual I-Squared conference. The prestigious award...
Precision Epigenomics Announces Nannon Roosa, PMP, CPA, FACMPE, as Vice President, Technology Licensing Strategy

Precision Epigenomics Announces Nannon Roosa, PMP, CPA, FACMPE, as Vice President, Technology Licensing Strategy

by Amy Cook | Jul 31, 2025 | Healthcare, News

Roosa joins the executive team to strengthen strategic initiatives surrounding laboratory licensing of the EPISEEK multicancer early detection tests and other laboratory products. Tucson, AZ — Precision Epigenomics is pleased to announce that Nannon Roosa will join...
Annual Association For Molecular Pathology Presentation

Annual Association For Molecular Pathology Presentation

by pesbm-sam | Feb 14, 2024 | Healthcare

Precision Epigenomics Inc. presents a bioinformatics study…
Digestive Disease Week Presentation

Digestive Disease Week Presentation

by pesbm-sam | Feb 10, 2024 | Healthcare

Precision Epigenomics Inc. presents a pilot study of the performance of EPISEEK™ for hepatocellular carcinoma at the Digestive Disease Week Annual Meeting 2023 in Chicago
« Older Entries

Recent Posts

  • Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond
  • Precision Epigenomics Joins the Conversation: Key Takeaways from Rosetta Fest
  • Precision Epigenomics Named “Startup of the Year” by University of Arizona, Honored for Pioneering Early Cancer Detection Technology
  • Precision Epigenomics Announces Nannon Roosa, PMP, CPA, FACMPE, as Vice President, Technology Licensing Strategy
  • Exploring Early Cancer Detection with the EPISEEK™ Liquid Biopsy: Insights from Dr. Joshua Routh on the Beautifully Broken Podcast

Recent Comments

No comments to show.
The EPISEEK™ test is recommended for use in adults with an elevated risk for cancer, such as those aged 45 or older. The EPISEEK™ test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK™ is intended to detect cancer signals. Use of EPISEEK™ is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected does not completely rule out cancer. A test result of Abnormal Methylation Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm or exclude the presence of cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK™ false positive) or confirmatory testing was insufficient to detect a very early cancer (follow up testing false negative). False positive (abnormal methylation signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Quick Links

Home
About
Tests
Resources
News
Contact

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way
Ste 280B
Tucson, AZ 85711



520.372.7522



520.777.7367

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow